Skip to content
Podofilox
Condylox (podofilox) is a small molecule pharmaceutical. Podofilox was first approved as Condylox on 1990-12-13. It is used to treat warts in the USA. The pharmaceutical is active against insulin-like growth factor 1 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Condylox (generic drugs available since 2002-01-29)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Podofilox
Tradename
Company
Number
Date
Products
CONDYLOXAllerganN-020529 RX1997-03-13
1 products, RLD, RS
CONDYLOXTevaN-019795 RX1990-12-13
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
condyloxNew Drug Application2019-11-15
podofiloxNDA authorized generic2023-03-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
warts—D014860B07
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BB: Antivirals, topical
— D06BB04: Podophyllotoxin
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CB: Podophyllotoxin derivatives, antineoplastic drugs
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Irritable bowel syndromeD043183EFO_0000555K58—23——5
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Barrett esophagusD001471EFO_0000280K22.71————1
Gastroesophageal refluxD005764EFO_0003948K211————1
Abdominal painD015746R10.91————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePODOFILOX
INN—
Description
Podophyllotoxin is an organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing a 3,4,5-trimethoxyphenyl substituent. It is found in the roots and rhizomes of Podophyllum species and is used for the topical treatment of genital warts. It has a role as an antineoplastic agent, a keratolytic drug, a tubulin modulator, a microtubule-destabilising agent, an antimitotic and a plant metabolite. It is a furonaphthodioxole, a lignan and an organic heterotetracyclic compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
Identifiers
PDB—
CAS-ID518-28-5
RxCUI8463
ChEMBL IDCHEMBL61
ChEBI ID50305
PubChem CID10607
DrugBankDB01179
UNII ID—
Target
Agency Approved
IGF1R
IGF1R
Organism
Homo sapiens
Gene name
IGF1R
Gene synonyms
NCBI Gene ID
3480
Protein name
insulin-like growth factor 1 receptor
Protein synonyms
CD221, IGF-I receptor, Insulin-like growth factor I receptor
Uniprot ID
Q9UCC0
Mouse ortholog
Igf1r (16001)
insulin-like growth factor 1 receptor (Q60751)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 169 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
683 adverse events reported
View more details